Necroptosis-Related Modification Patterns Depict the Tumor Microenvironment, Redox Stress Landscape, and Prognosis of Ovarian Cancer

被引：1
作者：
Geng R. [1 ]
Zhong Z. [1 ]
Ni S. [1 ]
Liu W. [1 ]
He Z. [1 ]
Gan S. [1 ]
Huang Q. [1 ]
Yu H. [1 ]
Bai J. [1 ]
Liu J. [2 ]
机构：
[1] Department of Biostatistics, School of Public Health, Nanjing Medical University, 101 Longmian Avenue, Jiangning District, Nanjing
[2] Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu, Nanjing
来源：
Oxidative Medicine and Cellular Longevity | 2023年 / 2023卷
关键词：
Cell death - Diagnosis - Diseases - Stem cells - Tumors;
D O I：
10.1155/2023/4945288
中图分类号：
学科分类号：
摘要：
Necroptosis is one of programmed cell death discovered recently, which involves in tumorigenesis, cancer metastasis, and immune reaction. We studied the necroptosis-related genes (NRGs) in ovarian cancer (OV) tissues using data from public databases, which separated into two NRGclusters. Patients in cluster A would have severe clinical characteristics, poor prognosis, and worse tumor microenvironment infiltration characteristics. The NRG score was achieved through the Cox analysis, along with a construction of a prognostic model. People with lower risk score would have better prognosis, lower expression of redox related genes, higher immunogenicity, and better effect on immunotherapy. In addition, the NRG score was closely related to cancer stem cell index, copy number variations, tumor mutation load, and chemosensitivity. We built a nomogram to enhance clinical application of the signature. These outcomes can help use know the function of NRGs in OV and provide new ideas for evaluating clinical outcome and developing more effective treatment protocols. © 2023 Rui Geng et al.
引用
收藏
相关论文
共 76 条
[1]  
Kuroki L., Guntupalli S.R., Treatment of epithelial ovarian cancer, BMJ, 371, (2020)
[2]  
Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F., Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: A Cancer Journal for Clinicians, 71, 3, pp. 209-249, (2021)
[3]  
Lheureux S., Braunstein M., Oza A.M., Epithelial ovarian cancer: Evolution of management in the era of precision medicine, CA: A Cancer Journal for Clinicians, 69, 4, pp. 280-304, (2019)
[4]  
Bast R.C., Matulonis U.A., Sood A.K., Ahmed A.A., Amobi A.E., Balkwill F.R., Wielgos-Bonvallet M., Bowtell D.D.L., Brenton J.D., Brugge J.S., Coleman R.L., Draetta G.F., Doberstein K., Drapkin R.I., Eckert M.A., Edwards R.P., Elias K.M., Ennis D., Futreal A., Gershenson D.M., Greenberg R.A., Huntsman D.G., Ji J.X.Y., Kohn E.C., Iavarone C., Lengyel E.R., Levine D.A., Lord C.J., Lu Z., Mills G.B., Modugno F., Nelson B.H., Odunsi K., Pilsworth J.A., Rottapel R.K., Powell D.J., Shen L., Shih I.M.,
[5]  
Peres L.C., Cushing-Haugen K.L., Kobel M., Harris H.R., Berchuck A., Rossing M.A., Schildkraut J.M., Doherty J.A., Invasive epithelial ovarian cancer survival by histotype and disease stage, Journal of the National Cancer Institute, 111, 1, pp. 60-68, (2019)
[6]  
Reid F., Bhatla N., Oza A.M., Blank S.V., Cohen R., Adams T., Benites A., Gardiner D., Gregory S., Suzuki M., Jones A., The world ovarian cancer coalition every woman study: Identifying challenges and opportunities to improve survival and quality of life, International Journal of Gynecological Cancer, 31, 2, pp. 238-244, (2021)
[7]  
Odunsi K., Immunotherapy in ovarian cancer, Annals of Oncology, 28, suppl_8, pp. viii1-viii7, (2017)
[8]  
Yang C., Xia B.R., Zhang Z.C., Zhang Y.J., Lou G., Jin W.L., Immunotherapy for ovarian cancer: Adjuvant, combination, and neoadjuvant, Frontiers in Immunology, 115, (2020)
[9]  
Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G., Molecular mechanisms of necroptosis: An ordered cellular explosion, Nature Reviews. Molecular Cell Biology, 11, 10, pp. 700-714, (2010)
[10]  
Najafov A., Chen H., Yuan J., Necroptosis and cancer, Trends Cancer, 3, 4, pp. 294-301, (2017)
12345678